Margulies, BarryNandjou, Midrelle E.2015-12-172015-12-172015-09-112015-08TSU2015Nandjouhttp://hdl.handle.net/11603/2072(M.S.) -- Towson University, 2015.Equine herpes virus type-1 (EHV-1) is responsible for a neurological infection in horses called equine herpes myeloencephalopathy (EHM). There is currently no specific treatment or vaccine licensed against the neuropathogenic EHV-1 strain (T953). In this study, the effect of combining the antiviral drugs cidofovir, foscarnet, and acyclovir was investigated. Specifically, we looked at the effect of using cidofovir + foscarnet and cidofovir + acyclovir against neuropathogenic EHV-1 (T953) propagated in equine dermal fibroblast (E. Derm) cells. This is the first study to look at the effect of combining different antiviral drugs against EHV-1 (T953). The combination of cidofovir (4 u/mL) + acyclovir (10 ?/mL) and cidofovir (7.5 ?/mL) + foscarnet (5 u/mL) were found to be non-toxic and to have an additive and no effect against EHV-1 (T953), respectively. These drug concentrations were also found to be non-toxic to E. Derm cells.application/pdfvii, 66 pagesengCopyright protected, all rights reserved.Text